Islet Cells from Human Embryonic Stem Cells
First Claim
Patent Images
1. A system for generating insulin expressing cells comprising a) a first in vitro population of cells comprising human embryonic stem cells;
- and b) a second isolated cell population comprising progeny of a portion of the first population of cells, wherein the progeny express insulin c-peptide.
2 Assignments
0 Petitions
Accused Products
Abstract
This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine.
99 Citations
11 Claims
-
1. A system for generating insulin expressing cells comprising a) a first in vitro population of cells comprising human embryonic stem cells;
- and b) a second isolated cell population comprising progeny of a portion of the first population of cells, wherein the progeny express insulin c-peptide.
- View Dependent Claims (2, 3, 4, 5)
-
6. A system for generating gut endoderm cells comprising a) a first in vitro population of cells comprising human embryonic stem cells;
- and b) a second cell population comprising progeny of a portion of the first population of cells, wherein the progeny express Sox17, HNF1a and HNF3P.
- View Dependent Claims (7, 8, 9)
-
10. A system for generating insulin expressing cells comprising a) a first in vitro population of cells which express stage specific embryonic antigen 3 (SSEA3), stage specific embryonic antigen 4 (SSEA4), and markers detectable using antibodies designated Tra-1-60 and Tra-1-81;
- and b) a second isolated cell population comprising progeny of a portion of the first population of cells, wherein the progeny express insulin c-peptide.
-
11. A system for generating gut endoderm cells comprising a) a first in vitro population of cells which express stage specific embryonic antigen 3 (SSEA3), stage specific embryonic antigen 4 (SSEA4) and markers detectable using antibodies designated Tra-1-60 and Tra-1-81;
- and b) a second cell population comprising progeny of a portion of the first population of cells, wherein the progeny express Sox17, HNF1α and
HNF3p.
- and b) a second cell population comprising progeny of a portion of the first population of cells, wherein the progeny express Sox17, HNF1α and
Specification